- Conditions
- Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 64
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congenital Heart Disease
- Interventions
- Entresto Pill, Placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure
- Interventions
- Sacubitril/valsartan, ACEi/ARB
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 42,269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Elevated Body Mass Index
- Interventions
- LIK066, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Heart Failure
- Interventions
- LCZ 696, Icatibant, placebo, Para-aminohippurate, Iohexol
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Peripheral Arterial Disease
- Interventions
- Entresto, Placebo group
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- LCZ696, Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 4,822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 110
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
- Conditions
- Hypertension
- Interventions
- LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 11
- States / cities
- Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
- Conditions
- Hypertension
- Interventions
- LCZ696, Valsartan, AHU377, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
- Conditions
- Chronic Heart Failure (CHF)
- Interventions
- LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 52
- States / cities
- Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
- Conditions
- Heart Failure
- Interventions
- REGN5381, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Torrance, California • Miami, Florida + 1 more
- Conditions
- Systolic Hypertension
- Interventions
- LCZ696, Valsartan, AHU377, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 19
- States / cities
- Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
- Conditions
- Chronic Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 251,831 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure
- Interventions
- LCZ696, valsartan, LCZ696 placebo, valsartan placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 38
- States / cities
- Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 129 more
- Conditions
- Chronic Heart Failure
- Interventions
- LCZ696, Valsartan, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more
- Conditions
- Hypertension, COVID
- Interventions
- ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pediatric Heart Failure
- Interventions
- LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 25
- States / cities
- Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Hemodialysis
- Interventions
- Sacubitril-valsartan, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Essential Hypertension
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 20 Years to 99 Years
- Enrollment
- 1,405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Heart Failure
- Interventions
- sacubitril/valsartan
- Drug
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,558 participants
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- LCZ696, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
- Conditions
- PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure
- Interventions
- Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Interventions
- Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee